A development-stage biopharmaceutical company that is focusing on developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer.


Updates from The Motley Fool

Latest updates on Provectus Pharmaceuticals from Fool.com.


Stock Performance

View Interactive PVCT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Provectus Pharmaceuticals.
Current Price: $0.04
Prev Close: $0.04
Open: $0.04
Bid: $0.00
Ask: $0.00
Day's Range: $0.04 - $0.04
52wk Range: $0.01 - $0.43
Volume: 2,359,834
Avg Vol 1,413,901
Market Cap: $9M
P/E (ttm): -0.47
EPS (ttm): ($0.09)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Provectus Pharmaceuticals.
CAPS Rating 1 out of 5
 
26 Outperform
23 Underperform
CAPS All Stars
 
2 Outperform
13 Underperform

How do you think Provectus Pharmaceuticals will perform against the market?



You pick for Provectus Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Peter R. Culpepper, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Provectus Pharmaceuticals.

A development-stage biopharmaceutical company that is focusing on developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer.

  • Exchange: NASDAQOTH
  • Sector: Healthcare
  • Industry: Drug Makers